Voyager Therapeutics (VYGR) Scheduled to Post Quarterly Earnings on Tuesday
Voyager Therapeutics (NASDAQ:VYGR) is scheduled to issue its quarterly earnings data before the market opens on Tuesday, March 13th. Analysts expect the company to announce earnings of ($0.74) per share for the quarter.
Voyager Therapeutics (VYGR) opened at $26.89 on Friday. Voyager Therapeutics has a one year low of $8.10 and a one year high of $31.91. The company has a market cap of $723.87 and a PE ratio of -9.47.
In related news, insider Dinah Ph.D. Sah sold 15,623 shares of the company’s stock in a transaction dated Tuesday, February 27th. The shares were sold at an average price of $30.00, for a total transaction of $468,690.00. Following the completion of the sale, the insider now owns 140,872 shares of the company’s stock, valued at $4,226,160. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Bernard Ravina sold 3,630 shares of the company’s stock in a transaction dated Wednesday, January 10th. The stock was sold at an average price of $16.40, for a total transaction of $59,532.00. Following the sale, the insider now directly owns 7,353 shares of the company’s stock, valued at approximately $120,589.20. The disclosure for this sale can be found here. Insiders have sold 27,194 shares of company stock valued at $647,757 in the last ninety days. 8.00% of the stock is currently owned by company insiders.
VYGR has been the topic of several research reports. Canaccord Genuity set a $26.00 price target on shares of Voyager Therapeutics and gave the company a “buy” rating in a research note on Wednesday, November 15th. Wedbush restated an “outperform” rating and issued a $26.00 price target (up from $22.00) on shares of Voyager Therapeutics in a research note on Monday, November 20th. Piper Jaffray Companies restated an “overweight” rating and issued a $28.00 price target on shares of Voyager Therapeutics in a research note on Tuesday, November 28th. BTIG Research initiated coverage on shares of Voyager Therapeutics in a research note on Tuesday, December 19th. They issued a “buy” rating and a $32.00 price target on the stock. Finally, BidaskClub upgraded shares of Voyager Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, January 5th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and ten have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $28.00.
About Voyager Therapeutics
Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.